Thursday Jul 24
3 Convincing Reasons To Buy Dendreon
Dendreon fell after first-quarter results failed to impress, but the company has solid opportunity in the prostate cancer drug market.
Dendreon Receives Consensus Recommendation of "Hold" from Analysts
Shares of Dendreon have been given an average rating of "Hold" by the nineteen ratings firms that are presently covering the stock, Analyst Ratings Network reports .
Why You Should Buy Dendreon's Drop
Biotechnology organization Dendreon's performance haasn't been extra ordinary in 2014.
Dendreon Short Interest Up 3.8% in June
Dendreon was the target of a large growth in short interest during the month of June.
New Provenge Data: Why Deerfield Investments Acquired A More Than 5% Stake In May
Followers of Dendreon may have noticed that since May, the stock has halted its downward march toward zero, finding support at $2.
What Does Dendreon Need To Succeed?
I know that my coverage of biotech Dendreon has been heavily slanted towards the negative side.